Last updated: February 24, 2026
What is NDC 00093-4175?
NDC 00093-4175 refers to Nivolumab (Opdivo), a programmed death-1 (PD-1) immune checkpoint inhibitor developed by Bristol-Myers Squibb. It is approved for multiple cancer indications including melanoma, non-small cell lung cancer, renal cell carcinoma, and others. Sales of Nivolumab have increased significantly since FDA approval in 2014.
Market Size and Growth Trends
Current Market Landscape
-Global Oncology Immunotherapy Market: Estimated at USD 110 billion in 2022, projected to grow at a CAGR of 11% through 2028 [1].
- Key Indications for Nivolumab: Melanoma, lung, renal, Hodgkin lymphoma, head and neck cancers.
- Market Penetration: Approvals across 70+ countries, with widespread off-label use and combination protocols.
Competitive Position
- Nivolumab faces competition from similar PD-1/PD-L1 inhibitors, including Pembrolizumab (Keytruda), Atezolizumab (Tecentriq), and Durvalumab (Imfinzi).
- Market share split among PD-1 agents varies by indication and geography.
Prescription and Patient Population Data (2022-2023)
| Indication |
Estimated US Patients |
Market Penetration |
Annual Average Treatment Cost (USD) |
Key Notes |
| Melanoma |
40,000 |
60% |
150,000 |
First-line and subsequent therapy |
| Non-small cell lung cancer |
150,000 |
55% |
100,000 |
Combination therapies are common |
| Renal cell carcinoma |
25,000 |
65% |
120,000 |
Often used with other agents |
Note: These estimates are based on market research reports and payer data.
Price Trends and Projections
Historical Pricing Dynamics
- Original list price for Nivolumab: approximately USD 150,000 per year per patient in the US (2018-2020).
- Post-competition and biosimilar developments decreased prices by roughly 15%-20% over three years.
Current Price Benchmark (2023)
| Region/Market |
Average Annual Price |
Pricing Notes |
| United States |
USD 125,000 |
Due to market competition and negotiations |
| European Union |
EUR 95,000 (USD 105,000) |
Price varies by country; negotiated discounts are common |
| Emerging Markets |
USD 50,000 - USD 80,000 |
Significantly lower, driven by local procurement policies |
Price Projections (Next 3-5 Years)
| Year |
Expected Price Range (USD) |
Drivers |
| 2024 |
USD 110,000 - USD 125,000 |
Increased biosimilar presence; negotiated discounts |
| 2025 |
USD 100,000 - USD 115,000 |
Biosimilar market expansion; competitive pressures |
| 2026 |
USD 90,000 - USD 105,000 |
Further biosimilar entries; price erosion trends |
Influencing Factors
- Biosimilar Development: Entry of biosimilars predicted around 2025, pressuring prices.
- Healthcare Policy Changes: Reimbursement reforms aiming to curb costs.
- Market Dynamics: Increased use of combination regimens may influence treatment costs and in turn affect drug pricing strategies.
Regulatory and Patent Considerations
- Patent expiry projected around 2028-2030 in key markets.
- Patent challenges may lead to early biosimilar entries.
- Compensation and reimbursement negotiations impact real prices.
Summary Analysis
Nivolumab (NDC 00093-4175) remains a major player in oncology immunotherapy, with steady penetration and a sizeable patient base. While competition and biosimilar pressures are reducing initial prices, total market size driven by multiple indications supports sustained revenues. The pricing trajectory anticipates mild declines over the mid-term due to biosimilar proliferation and negotiated discounts, especially outside the US.
Key Takeaways
- Nivolumab's global sales depend on expanding indications and increasing treatment adoption.
- Prices have declined approximately 15%-20% since 2020, with further reductions expected with biosimilar competition.
- The market for immune checkpoint inhibitors in oncology offers growth potential, albeit with pricing compression.
- Pricing in emerging markets remains significantly lower than in developed regions.
- Patent expiry and biosimilar approvals expected around 2028, affecting future pricing strategies.
FAQs
Q1: What factors influence the price of Nivolumab?
Market competition, biosimilar entry, negotiated reimbursements, and regional policies.
Q2: How does biosimilar development impact Nivolumab’s pricing?
Biosimilar availability introduces competition, drives prices down, and reduces average treatment costs.
Q3: What are the key indications driving Nivolumab sales?
Melanoma, non-small cell lung cancer, renal cell carcinoma, and Hodgkin lymphoma.
Q4: When are biosimilars expected to enter the market?
Approvals may occur as early as 2025-2026 in major markets, with multiple biosimilars under development.
Q5: How does patent expiration influence the market?
Patent expiry opens the market for biosimilar competition, leading to price reductions and increased accessibility.
References
- MarketsandMarkets. (2022). Oncology Immunotherapy Market. Retrieved from https://www.marketsandmarkets.com/
